- Home
- IKNA vs NVNO Comparison
IKNA vs NVNO Comparison
Compare IKNA & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- NVNO
- Stock Information
- Founded
- IKNA 2016
- NVNO 1987
- Country
- IKNA United States
- NVNO United States
- Employees
- IKNA N/A
- NVNO N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- IKNA Health Care
- NVNO Health Care
- Exchange
- IKNA Nasdaq
- NVNO Nasdaq
- Market Cap
- IKNA 61.8M
- NVNO 71.0M
- IPO Year
- IKNA 2021
- NVNO N/A
- Fundamental
- Price
- IKNA $1.35
- NVNO $3.99
- Analyst Decision
- IKNA Strong Buy
- NVNO
- Analyst Count
- IKNA 1
- NVNO 0
- Target Price
- IKNA $4.00
- NVNO N/A
- AVG Volume (30 Days)
- IKNA 79.7K
- NVNO 140.4K
- Earning Date
- IKNA 08-07-2025
- NVNO 07-30-2025
- Dividend Yield
- IKNA N/A
- NVNO N/A
- EPS Growth
- IKNA N/A
- NVNO N/A
- EPS
- IKNA N/A
- NVNO N/A
- Revenue
- IKNA N/A
- NVNO N/A
- Revenue This Year
- IKNA N/A
- NVNO N/A
- Revenue Next Year
- IKNA N/A
- NVNO N/A
- P/E Ratio
- IKNA N/A
- NVNO N/A
- Revenue Growth
- IKNA N/A
- NVNO N/A
- 52 Week Low
- IKNA $0.97
- NVNO $2.03
- 52 Week High
- IKNA $1.94
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- IKNA 53.36
- NVNO 51.05
- Support Level
- IKNA $1.31
- NVNO $3.86
- Resistance Level
- IKNA $1.38
- NVNO $4.36
- Average True Range (ATR)
- IKNA 0.06
- NVNO 0.31
- MACD
- IKNA -0.01
- NVNO -0.05
- Stochastic Oscillator
- IKNA 15.79
- NVNO 14.94
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.